- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
- Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
- Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
- No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
- Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
- Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
- Cassava Sciences Appoints Three New Members to its Board of Directors
- Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
- Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
- MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
More ▼
Key statistics
On Thursday, Cassava Sciences Inc (SAVA:NAQ) closed at 20.29, 64.69% above the 52 week low of 12.32 set on Oct 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.26 |
---|---|
High | 20.68 |
Low | 20.03 |
Bid | 20.05 |
Offer | 20.28 |
Previous close | 20.42 |
Average volume | 484.04k |
---|---|
Shares outstanding | 43.25m |
Free float | 40.14m |
P/E (TTM) | -- |
Market cap | 877.46m USD |
EPS (TTM) | -2.32 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼